Published in Lancet on September 08, 2007
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Incorporating lag time to benefit into prevention decisions for older adults. JAMA (2013) 2.40
Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (2015) 2.19
Impact of electronic health record clinical decision support on diabetes care: a randomized trial. Ann Fam Med (2011) 2.11
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension (2011) 2.02
Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension (2010) 2.02
Decade-long trends in mortality among patients with and without diabetes mellitus at a major academic medical center. JAMA Intern Med (2014) 2.01
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ (2008) 1.89
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol (2010) 1.81
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) (2011) 1.59
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Complexity of diabetic nephropathy pathogenesis and design of investigations. J Renal Inj Prev (2013) 1.49
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes (2014) 1.44
Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J (2008) 1.44
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol (2010) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol (2011) 1.41
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. Diabetes Technol Ther (2015) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol (2014) 1.33
The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin (2009) 1.30
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care (2016) 1.29
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Does diabetes double the risk of depression? Ann Fam Med (2009) 1.24
Reducing dietary sodium and decreases in cardiovascular disease in Canada. Can J Cardiol (2008) 1.24
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol (2010) 1.16
Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care (2013) 1.16
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol (2014) 1.15
Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Eur Psychiatry (2011) 1.15
Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil (2011) 1.15
Vascular outcome in type 2 diabetes: an ADVANCE? Lancet (2007) 1.14
Clinical complexity in middle-aged and older adults with diabetes: the Health and Retirement Study. Med Care (2010) 1.14
The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract (2010) 1.13
Impact of diabetes on cardiovascular disease: an update. Int J Hypertens (2013) 1.13
Exercise therapy in type 2 diabetes. Acta Diabetol (2009) 1.12
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Hypertension in diabetes: a call to action. Can J Cardiol (2009) 1.10
Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol (2010) 1.09
Annual adult health checkup: update on the Preventive Care Checklist Form(©). Can Fam Physician (2012) 1.08
Safety of very tight blood glucose control in type 2 diabetes. BMJ (2008) 1.07
Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10). PLoS One (2009) 1.06
Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: an epidemiological study of hypertension in a rural population in China. BMC Public Health (2011) 1.05
Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care (2011) 1.05
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
Diabetes & coronary heart disease: current perspectives. Indian J Med Res (2010) 1.03
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update. Can J Cardiol (2009) 1.03
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes (2013) 1.02
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Daily steps are low year-round and dip lower in fall/winter: findings from a longitudinal diabetes cohort. Cardiovasc Diabetol (2010) 1.00
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
The 2008 Canadian Hypertension Education Program recommendations: the scientific summary -- an annual update. Can J Cardiol (2008) 0.98
What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci (2012) 0.97
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol (2011) 0.97
Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia (2012) 0.96
Diabetes and the risk of heart failure. Heart Fail Clin (2011) 0.96
Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care (2012) 0.95
Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol (2010) 0.95
Level of blood pressure above goal and clinical inertia in a Medicaid population. J Am Soc Hypertens (2010) 0.95
Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS (2011) 0.95
A summary of the ADVANCE Trial. Diabetes Care (2009) 0.94
Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol (2010) 0.94
Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control (2013) 0.92
Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Diabetes Care (2010) 0.92
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag (2009) 0.92
Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc (2012) 0.92
Cost-effectiveness of an electronic medical record based clinical decision support system. Health Serv Res (2012) 0.92
Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab (2014) 0.91
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol (2009) 0.91
Diabetes and coronary heart disease: a risk factor for the global epidemic. Int J Hypertens (2012) 0.91
Blood pressure: the lower, the better: the con side. Diabetes Care (2011) 0.91
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol (2016) 0.90
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
The glomerular permeability determined by dextran clearance using Sephadex gel filtration. Scand J Clin Lab Invest (1968) 10.35
British Hypertension Society guidelines for hypertension management 1999: summary. BMJ (1999) 8.80
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform (1999) 7.68
Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol (1991) 7.67
Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ (2000) 7.36
Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation (1997) 7.03
Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens (1999) 6.74
Evaluation of nurse triage in a British accident and emergency department. BMJ (1992) 6.71
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80
Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell (2000) 5.73
Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev (2007) 5.63
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med (1984) 5.35
Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. BMJ (1997) 5.26
Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med (1984) 5.21
Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med (1995) 5.12
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet (2006) 5.11
The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology (1995) 5.08
Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet (1997) 5.04
Cardiovascular mortality in Dutch men during 1996 European football championship: longitudinal population study. BMJ (2001) 4.87
Awareness, treatment, and control of hypertension in Canada. Am J Hypertens (1997) 4.76
Structure and sequence of the rfb (O antigen) gene cluster of Salmonella serovar typhimurium (strain LT2). Mol Microbiol (1991) 4.76
Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol (2004) 4.67
Geographical variations in senile osteoporosis. The association with physical activity. J Bone Joint Surg Br (1970) 4.56
A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ (1998) 4.44
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
The epidemiology of heart failure. Eur Heart J (1997) 4.31
MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry (2006) 4.16
Estimates of general practitioner workload: a review. J R Coll Gen Pract (1989) 4.04
Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke (2001) 3.99
Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation (2001) 3.96
Management of raised blood pressure in New Zealand: a discussion document. BMJ (1993) 3.96
J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet (1994) 3.95
HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS (2001) 3.92
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet (1999) 3.80
Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology (1994) 3.75
Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens (2003) 3.67
Who should own scientific papers? Science (1998) 3.62
Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J Bacteriol (1994) 3.61
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis (1998) 3.50
External validation is necessary in prediction research: a clinical example. J Clin Epidemiol (2003) 3.49
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ (1995) 3.42
Genome-wide survey of protein kinases required for cell cycle progression. Nature (2004) 3.40
Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol (1995) 3.38
Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol (1998) 3.37
Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques (1993) 3.36
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet (2001) 3.32
The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology (1994) 3.30
Conflicts regarding decisions to limit treatment: a differential diagnosis. JAMA (2000) 3.27
Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J (1999) 3.18
Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension (1989) 3.13
Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull (1994) 3.09
The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J (2001) 3.07
Randomised studies of income supplementation: a lost opportunity to assess health outcomes. J Epidemiol Community Health (1999) 3.05
Txt2stop: a pilot randomised controlled trial of mobile phone-based smoking cessation support. Tob Control (2009) 3.05
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol (1992) 3.00
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) (1982) 2.99
Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation (2005) 2.99
Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ (1992) 2.98
Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens (2001) 2.96
Living near a main road and the risk of wheezing illness in children. Am J Respir Crit Care Med (2001) 2.94
Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol (1997) 2.92
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90
Funding of long term care for older people needs to be publicly debated. BMJ (2000) 2.90
Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet (1988) 2.84
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia (1997) 2.82
Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet (1998) 2.82
Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol (1996) 2.80
Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke (1997) 2.79